Identifying risk factors and optimizing standard of care for patients with acquired haemophilia A: Results from a Czech patient cohort

Haemophilia ◽  
2020 ◽  
Vol 26 (4) ◽  
pp. 643-651
Author(s):  
Peter Salaj ◽  
Vera Geierová ◽  
Eva Ivanová ◽  
Jan Loužil ◽  
Viera Pohlreichová ◽  
...  
Keyword(s):  
Risk Factors ◽  
Standard Of Care ◽  
Haemophilia A ◽  
Patient Cohort ◽  
Acquired Haemophilia ◽  
Czech Patient

scholarly journals Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis

2018 ◽  
pp. bcr-2018-226588 ◽  
Author(s):  
Jarrett Madeley ◽  
Georgina Hodges ◽  
Andrew Birchley
Keyword(s):  
Risk Factors ◽  
Multiple Sclerosis ◽  
Previous Treatment ◽  
Haemophilia A ◽  
Fviii Inhibitor ◽  
Acquired Haemophilia ◽  
Autoimmune Conditions ◽  
Traditional Risk Factors ◽  
Patient’S History ◽  
Cessation Of Treatment

This case illustrates a 36-year-old man who presented with a factor VIII (FVIII) inhibitor (acquired haemophilia A) with cutaneous bleeding and a significant thigh haematoma. No traditional risk factors for the development of a FVIII inhibitor were identified. However, previous treatment with alemtuzumab for multiple sclerosis was noted in the patient’s history. Alemtuzumab is an anti-CD52 monoclonal antibody and is known to be associated with the development of a number of autoimmune conditions, with a delay in onset of these conditions as long as 5 years after the cessation of treatment. To our knowledge, there have only been three previously documented cases of a FVIII inhibitor in the setting of alemtuzumab therapy. This case adds further evidence to the current body of literature suggesting alemtuzumab as a causative agent for the development of an FVIII inhibitor.

Clinical features and outcome of acquired haemophilia A

2010 ◽  
Vol 30 (03) ◽  
pp. 156-161 ◽  
Author(s):  
R. Gheisari ◽  
B. Bomke ◽  
T. Hoffmann ◽  
R. E. Scharf
Keyword(s):  
Respiratory Diseases ◽  
Care Center ◽  
Treatment Algorithm ◽  
Early Death ◽  
Underlying Disease ◽  
Pulmonary Sarcoidosis ◽  
Relative Increase ◽  
Laboratory Evaluation ◽  
Haemophilia A ◽  
Acquired Haemophilia

SummaryWe have performed a monocenter study on 29 consecutive patients with acquired haemophilia A who were referred for diagnosis and treatment to the Düsseldorf Haemophilia Comprehensive Care Center between March 2001 and February 2010. Patients, methods: 18 men (age: 44–86 years) and 11 women (age: 20–83 years). For laboratory evaluation, a standardized staged protocol of aPTT, FVIII : C activity and concentration, mixing studies with patient and normal plasma, and quantification of inhibitor titers (Bethesda assay) was used. Diagnostic work-up included elaborate examinations for any underlying disease. Results: In 18 (62%) of the 29 patients with acquired haemophilia A, an underlying disorder was identified, including 9 patients with respiratory diseases (31%), 7 patients with autoimmune disorders (24%), one with malignancy, and one with postpartum state, while in 11 patients (38%) acquired haemophilia A remained idiopathic. Haemotherapy of bleeding, suppression or elimination of the inhibitor, and induction of immunotolerance to endogenous FVIII:C were performed according to a treatment algorithm. Predefined clinical endpoints were control of bleeding, eradication of the inhibitor, complete or partial remission (CR, PR), relapse, or early death (≤30 days). Of the 29 patients in total, 22 individuals achieved CR (76%), three had PR, one relapsed, and three died within 30 days (one of acute myocardial infarction while on anti-haemorrhagic treatment, one of sepsis while on immunosuppression due to active acquired haemophilia A, one of lung bleeding in association with pre-existing pulmonary sarcoidosis). Conclusion: This monocenter study demonstrates that control of life-threatening bleeding, eradication of the inhibitor, and induction of tolerance to endogenous FVIII have significantly improved the clinical outcome of acquired haemophilia A. Our data also suggest a shift in underlying disorders associated with acquired haemophilia A, whereby, in comparison to published studies, a relative increase in the proportion of patients with respiratory diseases is present.

Experience in the Treatment of Acquired Haemophilia A (AHA) in 26 Patients in Relation to Bleeding Control and Induction of Immune Tolerance

2019 ◽  
Author(s):  
G. Di Prinzio ◽  
G. Goldmann ◽  
S. Horneff ◽  
C. Klein ◽  
N. Marquardt ◽  
...  
Keyword(s):  
Immune Tolerance ◽  
Haemophilia A ◽  
Bleeding Control ◽  
Acquired Haemophilia

scholarly journals Advances in the understanding of acquired haemophilia A: implications for clinical practice

2010 ◽  
Vol 148 (2) ◽  
pp. 183-194 ◽  
Author(s):  
Peter W. Collins ◽  
Charles L. Percy
Keyword(s):  
Clinical Practice ◽  
Haemophilia A ◽  
Acquired Haemophilia

scholarly journals Single centre experience on Acquired Haemophilia A patients: Diagnosis, clinical management and analysis of factors predictive of response and outcome

Haemophilia ◽  
2021 ◽  
Author(s):  
Marika Porrazzo ◽  
Erminia Baldacci ◽  
Antonietta Ferretti ◽  
Maria Lucia De Luca ◽  
Francesco Barone ◽  
...  
Keyword(s):  
Clinical Management ◽  
Haemophilia A ◽  
Single Centre ◽  
Acquired Haemophilia ◽  
Single Centre Experience

A case of acquired haemophilia A complicated by peritonitis after distal gastrectomy

Haemophilia ◽  
2016 ◽  
Vol 22 (5) ◽  
pp. e469-e471 ◽  
Author(s):  
K. Sato ◽  
N. Tsukada ◽  
J. Inamura ◽  
M. Kon ◽  
S. Ito ◽  
...  
Keyword(s):  
Distal Gastrectomy ◽  
Haemophilia A ◽  
Acquired Haemophilia

Relapse pattern and long‐term outcomes in subjects with acquired haemophilia A

Haemophilia ◽  
2019 ◽  
Vol 25 (2) ◽  
pp. 252-257 ◽  
Author(s):  
Terry Mizrahi ◽  
Karine Doyon ◽  
Evemie Dubé ◽  
Arnaud Bonnefoy ◽  
Margaret Warner ◽  
...  
Keyword(s):  
Haemophilia A ◽  
Long Term Outcomes ◽  
Acquired Haemophilia ◽  
Relapse Pattern

Successful bleeding control with recombinant porcine factor VIII in reduced loading doses in two patients with acquired haemophilia A and failure of bypassing agent therapy

Haemophilia ◽  
2016 ◽  
Vol 22 (5) ◽  
pp. e472-e474 ◽  
Author(s):  
M. Stemberger ◽  
P. Möhnle ◽  
J. Tschöp ◽  
L. Ney ◽  
M. Spannagl ◽  
...  
Keyword(s):  
Factor Viii ◽  
Haemophilia A ◽  
Bleeding Control ◽  
Acquired Haemophilia

A low dose rituximab regimen for first‐line treatment of acquired haemophilia A

2021 ◽  
Author(s):  
Stewart Hunt ◽  
Jeremy Robertson ◽  
Jason Conn ◽  
John Casey ◽  
Jane Royle ◽  
...  
Keyword(s):  
Low Dose ◽  
Haemophilia A ◽  
Line Treatment ◽  
First Line ◽  
Acquired Haemophilia ◽  
First Line Treatment

scholarly journals Acquired haemophilia A caused by inhibitor against factor VIII.

2001 ◽  
Vol 90 (6) ◽  
pp. 1085-1087
Author(s):  
Noriko Kakudo ◽  
Tomohiro Sugawara ◽  
Yasuhide Asaumi ◽  
Tatsuyuki Sato ◽  
Mitsushi Yano ◽  
...  
Keyword(s):  
Factor Viii ◽  
Haemophilia A ◽  
Acquired Haemophilia
Sign in / Sign up

Export Citation Format

Share Document